Merck’s Keytruda And Seagen’s Padcev Become First PD-1/ADC Combo To Win US Approval

In Urothelial Carcinoma

 
• By Ayisha Sharma
Stamp of approval
The Approval Extends Padcev's Use To The First Line Setting • Source: Shutterstock

More from New Products

More from Scrip